Launch week offerEnds in00h00m00s

annual Promonthly Pro

G. Niklas Norén

Chief Science Officer

Internal Displacement Monitoring Centre

Sweden

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in Sweden

About

Dr. G. Niklas Norén serves as the Chief Science Officer at Uppsala Monitoring Centre in Sweden. His research focuses on pharmacovigilance, particularly in the areas of adverse drug reactions, drug-drug interactions, and statistical signal detection. Recent publications include studies on consensus clustering for case series identification and the communication of adverse drug reaction insights through patient organizations.

Articles (19)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (9)

Nicole Pratt

University of South Australia

AUSTRALIA

View details

Eelko Hak

professor

University of Groningen

NETHERLANDS

View details

Daniel R. Morales

University of Edinburgh

UNITED KINGDOM

View details

Peter Rijnbeek

Erasmus MC

NETHERLANDS

View details

Peter Hjelmstrom

Director/Chief Executive Officer

Internal Displacement Monitoring Centre

SWEDEN

View details

Samantha Martin

Head of Research

Drug Safety Research Unit

UNITED KINGDOM

View details

Jeffrey Aronson

University of Oxford

UNITED KINGDOM

View details

Thamir M. Alshammari

Associate professor

jazan university

SAUDI ARABIA

View details

catharina schuiling-veninga

University of Groningen

NETHERLANDS

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

G. Niklas Norén

Research Interests

Make your next move.

Explore related searches

About

Articles (19)

Exploring the Reliability of Detecting Drug–Drug Interactions that Increase the Risk of Gestational Diabetes in Adverse Event Reporting Systems

A Scalable Predictive Modeling Approach to Duplicate Detection in Pharmacovigilance: Algorithm Development and Validation Study

Artificial Intelligence in Pharmacovigilance: Guiding Principles from the CIOMS Working Group XIV

International Medicinal Product Information Documents: A Quantitative Content Analysis of Instructions for Preventing, Mitigating, and Monitoring Adverse Drug Reactions

Critical Appraisal of Artificial Intelligence for Rare-Event Recognition: Principles and Pharmacovigilance Case Studies

VigiBase: Resource Profile Update with a Summary of Global Patterns and Trends in Adverse Event Reports for Medicines and Vaccines

Recommendations to enable broader use of real-world evidence to inform decision-making throughout pharmacovigilance signal management

Correction: Charting and Sidestepping the Pitfalls of Disproportionality Analysis

Charting and Sidestepping the Pitfalls of Disproportionality Analysis

Signals of Adverse Reactions to Herbal Medicines: Evidence and Document Analysis Based on a Scoping Review

Interplay of Spontaneous Reporting and Longitudinal Healthcare Databases for Signal Management: Position Statement from the Real-World Evidence and Big Data Special Interest Group of the International Society of Pharmacovigilance

Clinical Relatedness and Stability of vigiVec Semantic Vector Representations of Adverse Events and Drugs in Pharmacovigilance

Consensus clustering for case series identification and adverse event profiles in pharmacovigilance

Communicating Adverse Drug Reaction Insights Through Patient Organizations: Experiences from a Pilot Study in the Netherlands

Pneumonia may be more frequent and have more fatal outcomes with clozapine than with other second‐generation antipsychotics

A Feasibility Study of Drug–Drug Interaction Signal Detection in Regular Pharmacovigilance

Correction to: Communicating Adverse Drug Reaction Insights Through Patient Organizations: Experiences from a Pilot Study in the Netherlands (Drug Safety, (2020), 43, 8, (745-749), 10.1007/s40264-020-00932-5)

Interstitial Lung Disease as an Adverse Drug Reaction in Japan: Exploration of Regulatory Actions as a Basis for High Reporting

Risk Factor Considerations in Statistical Signal Detection: Using Subgroup Disproportionality to Uncover Risk Groups for Adverse Drug Reactions in VigiBase

Collaborators (9)

Nicole Pratt

Eelko Hak

Daniel R. Morales

Peter Rijnbeek

Peter Hjelmstrom

Samantha Martin

Jeffrey Aronson

Thamir M. Alshammari

catharina schuiling-veninga

Make your next move.